{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:07Z","timestamp":1787988007924,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","award":["14329"],"award-info":[{"award-number":["14329"]}],"id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FWO","award":["1833222N"],"award-info":[{"award-number":["1833222N"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00259-026-08020-z","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:49:04Z","timestamp":1782182944000},"page":"6569-6582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of [\u00b9\u2078F]AlF-NOTA-octreotide PET\/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patients"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9080-2370","authenticated-orcid":false,"given":"Hannes","family":"Leupe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie-Anne","family":"De Buyst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Dekervel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Cleeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloefar","family":"Ahmadi Bidakhvidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Dooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Jentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennert","family":"Boeckxstaens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van Herpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan","family":"Rasschaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Koole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Bormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Verslype","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6080-1577","authenticated-orcid":false,"given":"Christophe M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"6","key":"8020_CR1","doi-asserted-by":"publisher","first-page":"e2515798","DOI":"10.1001\/jamanetworkopen.2025.15798","volume":"8","author":"A Dasari","year":"2025","unstructured":"Dasari A, Wallace K, Halperin DM, Maxwell J, Kunz P, Singh S, et al. Epidemiology of Neuroendocrine Neoplasms in the US. JAMA Netw Open. 2025;8(6):e2515798. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.15798.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"8020_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol"},{"issue":"4","key":"8020_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring the Rising Incidence of Neuroendocrine Tumors: A Population-Based Analysis of Epidemiology, Metastatic Presentation, and Outcomes. Cancer. 2015;121(4):589\u201397. https:\/\/doi.org\/10.1002\/cncr.29099.\u00a0","journal-title":"Cancer"},{"key":"8020_CR4","doi-asserted-by":"crossref","unstructured":"White B, Bouvier C, Genus T, Rous B, Srirajaskanthan R, Chandrakumaran K et al. Incidence and prevalence of neuroendocrine neoplasms reported in England from 2015 to 2017. 17th Annual Meeting of the UK and Ireland Neuroendocrine Tumour Society 2019. Endocrine Abstracts. 2019 Dec 2.","DOI":"10.1530\/endoabs.68.OC3"},{"key":"8020_CR5","doi-asserted-by":"publisher","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology. Springer; 2022. pp. 115\u201354. https:\/\/doi.org\/10.1007\/s12022-022-09708-2.","DOI":"10.1007\/s12022-022-09708-2"},{"issue":"9","key":"8020_CR6","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F\u2013DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588\u2013601. https:\/\/doi.org\/10.1007\/s00259-017-3728.\u00a0","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"8020_CR7","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2967\/jnumed.123.266185","volume":"64","author":"T Al-Toubah","year":"2023","unstructured":"Al-Toubah T, Montilla-Soler J, El-Haddad G, Haider M, Strosberg J. Somatostatin Receptor Expression in Lung Neuroendocrine tumors: An Analysis of DOTATATE PET scans. J Nucl Med. 2023;64(12):1895\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.266185.\u00a0","journal-title":"J Nucl Med"},{"issue":"10","key":"8020_CR8","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1210\/clinem\/dgad","volume":"108","author":"A Fischer","year":"2023","unstructured":"Fischer A, Kloos S, Maccio U, Friemel J, Remde H, Fassnacht M, et al. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses. J Clin Endocrinol Metab. 2023;108(10):2676\u201385. https:\/\/doi.org\/10.1210\/clinem\/dgad.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"8020_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2967\/jnumed.117.202275","volume":"59","author":"TA Hope","year":"2018","unstructured":"Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018;59(1):66\u201374. https:\/\/doi.org\/10.2967\/jnumed.117.202275.\u00a0","journal-title":"J Nucl Med"},{"key":"8020_CR10","doi-asserted-by":"publisher","unstructured":"Hope TA. Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET. J Nucl Med. 2020;61(12):1764. https:\/\/doi.org\/10.2967\/jnumed.120.257808.","DOI":"10.2967\/jnumed.120.257808"},{"issue":"2","key":"8020_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.122.264860","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, et al. SNMMI Procedure Standard\/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023;64(2):204\u201310. https:\/\/doi.org\/10.2967\/jnumed.122.264860.\u00a0","journal-title":"J Nucl Med"},{"key":"8020_CR12","doi-asserted-by":"publisher","unstructured":"Pavel M, De Herder WW. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors. Neuroendocrinology., Karger S. AG; 2017. pp. 193\u20135. https:\/\/doi.org\/10.1159\/000457957","DOI":"10.1159\/000457957"},{"issue":"5","key":"8020_CR13","first-page":"311","volume":"8","author":"E Pauwels","year":"2018","unstructured":"Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311\u201331.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"6","key":"8020_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2967\/jnumed.123.265622","volume":"64","author":"H Leupe","year":"2023","unstructured":"Leupe H, Ahenkorah S, Dekervel J, Unterrainer M, Van Cutsem E, Verslype C, et al. 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use. J Nucl Med. 2023;64(6):835\u201341. https:\/\/doi.org\/10.2967\/jnumed.123.265622.\u00a0","journal-title":"J Nucl Med"},{"issue":"4","key":"8020_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-019-0084-1","volume":"5","author":"T Tshibangu","year":"2020","unstructured":"Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, et al. Automated GMP compliant production of [18F]AlF-NOTA-octreotide. EJNMMI Radiopharm Chem. 2020;5(4):1\u201323. https:\/\/doi.org\/10.1186\/s41181-019-0084-1.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"13","key":"8020_CR16","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","volume":"47","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47(13):3033\u201346. https:\/\/doi.org\/10.1007\/s00259-020-04918-4.\u00a0","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"8020_CR17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11307-021-01628-7","volume":"23","author":"J Hou","year":"2021","unstructured":"Hou J, Long T, Yang N, Chen D, Zeng S, Zheng K, et al. Biodistribution of 18F-AlF-NOTA-octreotide in Different Organs and Characterization of Uptake in Neuroendocrine Neoplasms. Mol Imaging Biol. 2021;23(6):827\u201335. https:\/\/doi.org\/10.1007\/s11307-021-01628-7.\u00a0","journal-title":"Mol Imaging Biol"},{"key":"8020_CR18","doi-asserted-by":"publisher","unstructured":"Hou J, Long T, He Z, Zhou M, Yang N, Chen D et al. Evaluation of 18F Alf NOTA octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET\/CT. EJNMMI Res. 2021;11(1):55. https:\/\/doi.org\/10.1186\/s13550-021-00797-4.","DOI":"10.1186\/s13550-021-00797-4"},{"issue":"2","key":"8020_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15020439","volume":"15","author":"A Haeger","year":"2023","unstructured":"Haeger A, Soza-Ried C, Kramer V, Hurtado de Mendoza A, Eppard E, Emmanuel N, et al. Al[18F]F-NOTA-Octreotide Is Comparable to [68Ga]Ga-DOTA-TATE for PET\/CT Imaging of Neuroendocrine Tumours in the Latin-American Population. Cancers (Basel). 2023;15(2):1\u201311. https:\/\/doi.org\/10.3390\/cancers15020439.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"8020_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/RLU.0000000000002578","volume":"44","author":"T Long","year":"2019","unstructured":"Long T, Yang N, Zhou M, Chen D, Li Y, Li J, et al. Clinical Application of 18F-AlF-NOTA-Octreotide PET\/CT in Combination with 18F-FDG PET\/CT for Imaging Neuroendocrine Neoplasms. Clin Nucl Med. 2019;44(6):452\u20138. 10.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"8020_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.122.264563","volume":"64","author":"E Pauwels","year":"2023","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, et al. 18F-AlF-NOTA-octreotide outperforms 68Ga-DOTA-TATE\/-NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med. 2023;64(4):632\u20138.","journal-title":"J Nucl Med"},{"issue":"53","key":"8020_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-023-01003-3","volume":"13","author":"L Boeckxstaens","year":"2023","unstructured":"Boeckxstaens L, Pauwels E, Vandecaveye V, Deckers W, Cleeren F, Dekervel J, et al. Prospective comparison of [18F]AlF-NOTA-octreotide PET\/MRI to [68Ga]Ga-DOTATATE PET\/CT in neuroendocrine tumor patients. EJNMMI Res. 2023;13(53):1\u201313. https:\/\/doi.org\/10.1186\/s13550-023-01003-3.","journal-title":"EJNMMI Res"},{"issue":"8","key":"8020_CR23","doi-asserted-by":"publisher","first-page":"e13420","DOI":"10.1111\/jne.13420","volume":"36","author":"H Leupe","year":"2024","unstructured":"Leupe H, Pauwels E, Vandamme T, Van den Broeck B, Lybaert W, Dekervel J, et al. Clinical impact of using [18F]AlF-NOTA\u2010octreotide PET\/CT instead of [68Ga]Ga\u2010DOTA\u2010SSA PET\/CT: Secondary endpoint analysis of a multicenter, prospective trial. J Neuroendocrinol. 2024;36(8):e13420. https:\/\/doi.org\/10.1111\/jne.13420.","journal-title":"J Neuroendocrinol"},{"key":"8020_CR24","doi-asserted-by":"publisher","unstructured":"Leupe H, Ahmadi Bidakhvidi N, Goffin K, Van den Broeck B, Jentjens S, Laenen A, et al. Comparison of inter- and intraobserver agreement between [18F]AlF-NOTA-octreotide and [68Ga]Ga-DOTA-SSA PET\/CT. EJNMMI Rep. 2025;9(1):17. https:\/\/doi.org\/10.1186\/s41824-025-00250-y.","DOI":"10.1186\/s41824-025-00250-y"},{"issue":"7","key":"8020_CR25","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.119","volume":"61","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Van Binnebeek S, Vandecaveye V, Baete K, Vanbilloen H, Koole M, et al. Inflammation-based index and 68ga-dotatoc pet-derived uptake and volumetric parameters predict outcome in neuroendocrine tumor patients treated with 90y-dotatoc. J Nucl Med. 2020;61(7):1014\u201320. https:\/\/doi.org\/10.2967\/jnumed.119.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08020-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08020-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:47Z","timestamp":1787986847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08020-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8020"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08020-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Ethische Commissie Onderzoek UZ\/KU Leuven S68607) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest (CoIs) relevant to this work exist. Nonrelated potential CoIs include: Christophe M. Deroose is\/has been a consultant for (fees received by institution): Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO, Immedica Pharma, Molecular Partners, Nuclear Research and consultancy. His institution has received travel fees from: GE Healthcare, Sirtex. Karolien Goffin received consultancy fees from Bayer, Novartis, Telix Pharmaceuticals, GE Healthcare, Lightpoint, Blue Earth Diagnostics, Merck Sharp & Dome, PSI CRO.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}